Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
23,588
Total Claims
$4.5M
Drug Cost
619
Beneficiaries
$7,219
Cost/Patient
Risk Score Breakdown 15/100
Score components are additive. Read full methodology
Peer Comparison vs. 110,156 Internal Medicine providers
+412%
Cost per patient vs peers
$7,219 vs $1,411 avg
+121%
Brand preference vs peers
23.5% vs 10.6% avg
Brand vs Generic
Brand: 5,416 claims · $3.9M
Generic: 17,636 claims · $584K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Icosapent Ethyl | 1,820 | $1.2M |
| Dapagliflozin Propanediol | 291 | $300K |
| Empagliflozin | 291 | $297K |
| Denosumab | 165 | $284K |
| Tenofovir Alafenamide | 148 | $220K |
| Diclofenac Epolamine | 295 | $180K |
| Semaglutide | 119 | $176K |
| Rsv Vacc, Pref A And Pref B/Pf | 429 | $125K |
| Sitagliptin Phosphate | 133 | $116K |
| Apixaban | 87 | $86K |
| Raloxifene Hcl | 885 | $84K |
| Lipase/Protease/Amylase | 62 | $80K |
| Dulaglutide | 38 | $71K |
| Linaclotide | 85 | $69K |
| Icosapent Ethyl | 134 | $67K |
Prescribing Profile
Patient Profile
74
Avg Age
52%
Female
0.99
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations of wrongdoing.Methodology · About · Dispute this data